Rubrik: Aktuelle Epidemiologie und Diagnostik in der Mikrobiologie
West Nil Virus: Ein Virus erobert Deutschland und Europa (S. 58)
1. Smithburn KC, Hughes TP, Burke AW, Paul JH. A neurotropic virus isolated from the blood of a native of Uganda. Am J Trop Med 1940; s1-20 (4): 471-492. doi:10.4269/ajtmh.1940.s1-20.471.
2. Nemeth NM, Oesterle PT, Bowen RA. Humoral immunity to West Nile virus is long-lasting and protective in the house sparrow (Passer domesticus). Am J Trop Med Hyg 2009; 80 (5): 864-869. doi: 10.4269/ajtmh.2009.80.864.
3. LaDeau SL, Kilpatrick AM, Marra PP. West Nile virus emergence and large-scale declines of North American bird populations. Nature 2007; 447 (7145): 710-713. doi: 10.1038/nature05829.
4. Bunning ML, Bowen RA, Cropp CB, Sullivan KG, Davis BS, Komar N, Godsey MS, Baker D, Hettler DL, Holmes DA, Biggerstaff BJ, Mitchell CJ. Experimental infection of horses with West Nile virus. Emerg Infect Dis 2002; 8 (4): 380-386. doi: 10.3201/eid0804.010239.
5. Hayes EB, Komar N, Nasci RS, Montgomery SP, O'Leary DR, Campbell GL. Epidemiology and transmission dynamics of West Nile virus disease. Emerg Infect Dis 2005; 11 (8): 1167-1173. doi: 10.3201/eid1108.050289a.
6. Campbell GL, Marfin AA, Lanciotti RS, Gubler DJ. West Nile virus. Lancet Infect Dis 2002; 2 (9): 519-29. doi: 10.1016/s1473-3099(02)00368-7.
7. Granwehr BP, Lillibridge KM, Higgs S, Mason PW, Aronson JF, Campbell GA, Barrett AD. West Nile virus: where are we now? Lancet Infect Dis 2004; 4 (9): 547-56. doi: 10.1016/S1473-3099(04)01128-4.
8. Davis LE, DeBiasi R, Goade DE, Haaland KY, Harrington JA, Harnar JB, Pergam SA, King MK, DeMasters BK, Tyler KL. West Nile virus neuroinvasive disease. Ann Neurol 2006; 60 (3): 286-300. doi: 10.1002/ana.20959.
9. Sejvar JJ. Clinical manifestations and outcomes of West Nile virus infection. Viruses 2014; 6 (2): 606-23. doi: 10.3390/v6020606.
10. Cendejas PM, Goodman AG. Vaccination and control methods of West Nile Virus infection in equids and humans. Vaccines (Basel) 2024; 12 (5): 485. doi: 10.3390/vaccines12050485.
11. Martinet JP, Ferté H, Failloux AB, Schaffner F, Depaquit J. Mosquitoes of North-Western Europe as potential vectors of Arboviruses: a review. Viruses. 2019; 11 (11): 1059. doi: 10.3390/v11111059.
12. Giesen C, Herrador Z, Fernandez-Martinez B, Figuerola J, Gangoso L, Vazquez A, Gómez-Barroso D. A systematic review of environmental factors related to WNV circulation in European and Mediterranean countries. One Health 2023; 16: 100478. doi: 10.1016/j.onehlt.2022.100478.
13. Ruiz-López MJ, Aguilera-Sepúlveda P, Cebrián-Camisón S, Figuerola J, Magallanes S, Varona S, Cuesta I, Cano-Gómez C, Sánchez-Mora P, Camacho J, Sánchez-Peña C, Marchena FJ, Ameyugo U, Ruíz S, Sánchez-Seco MP, Agüero M, Jiménez-Clavero MÁ, Fernández-Pinero J, Vázquez A. Re-Emergence of a West Nile Virus (WNV) variant in South Spain with rapid spread capacity. Viruses 2023; 15 (12): 2372. doi: 10.3390/v15122372.
14. Bahuon C, Marcillaud-Pitel C, Bournez L, Leblond A, Beck C, Hars J, Leparc-Goffart I, L'Ambert G, Paty MC, Cavalerie L, Daix C, Tritz P, Durand B, Zientara S, Lecollinet S. West Nile virus epizootics in the Camargue (France) in 2015 and reinforcement of surveillance and control networks. Rev Sci Tech 2016; 35 (3): 811-824. doi: 10.20506/rst.35.3.2571.
15. Pichler V, Giammarioli C, Bellini R, Veronesi R, Arnoldi D, Rizzoli A, Lia RP, Otranto D, Ballardini M, Cobre P, Serini P, Della Torre A, Caputo B. First evidence of pyrethroid resistance in Italian populations of West Nile virus vector Culex pipiens. Med Vet Entomol 2022; 36 (3): 390-395. doi: 10.1111/mve.12573.
16. Balatsos G, Beleri S, Tegos N, Bisia M, Karras V, Zavitsanou E, Papachristos DP, Papadopoulos NT, Michaelakis A, Patsoula E. Overwintering West Nile virus in active Culex pipiens mosquito populations in Greece. Parasit Vectors 2024; 17 (1): 286. doi: 10.1186/s13071-024-06367-6.
17. Cazzin S, Liechti N, Jandrasits D, Flacio E, Beuret C, Engler O, Guidi V. First Detection of West Nile Virus Lineage 2 in Mosquitoes in Switzerland, 2022. Pathogens 2023; 12 (12): 1424. doi: 10.3390/pathogens12121424.
18. Kampen H, Holicki CM, Ziegler U, Groschup MH, Tews BA, Werner D. West Nile Virus Mosquito Vectors (Diptera: Culicidae) in Germany. Viruses 2020 28; 12 (5): 493. doi: 10.3390/v12050493.
19. Kampen H, Tews BA, Werner D. First evidence of West Nile Virus overwintering in mosquitoes in Germany. Viruses. 2021; 13 (12): 2463. doi: 10.3390/v13122463.
20. Rau J, Köchling K, Schäfer M, Tews BA, Wylezich C, Schaub GA, Werner D, Kampen H. Viral RNA in mosquitoes (Diptera: Culicidae) collected between 2019 and 2021 in Germany. Viruses 2023; 15 (12): 2298. doi: 10.3390/v15122298.
21. Ständige Impfkommission Veterinärmedizin (StIKo Vet) am Friedrich-Loeffler-Institut (FLI). Stellungnahme zur Immunisierung von Pferden gegen das West-Nil-Virus. https://www.openagrar.de/servlets/MCRFileNodeServlet/openagrar_derivate_00017232/Stellungnahme_WNV-Impfung_Pferde_2018-10-22.pdf.
22. Ständige Impfkommission Veterinärmedizin (StIKo Vet) am Friedrich-Loeffler-Institut (FLI). Leitlinie zur Impfung von Pferden. Stand 01.03.2023. https://www.tieraerzteverband.de/bpt/berufspolitik/leitlinien/dokumente/impfleitlinien/Impfleitlinie-Pferd_2023-03-01.pdf.
23. European Centre for Disease Prevention and Control (ECDC). West Nile virus infection - Annual Epidemiological Report for 2018. https://www.ecdc.europa.eu/sites/default/files/documents/west-nile-fever-annual-epidemiological-report-2018.pdf.
24. Robert-Koch Institut (RK). https://survstat.rki.de/Content/Query/Create.aspx.
25. Frank C, Lachmann R. Saison 2024 steckmückenübertragener Krankheitserreger in Deutschland beginnt. Epid Bull 2024; 29: 14-16. doi: 10.25646/12221.
26. Niedersächsisches Landesgesundheitsamt (NLGA). Erster Fall von West-Nil-Fieber bei einem Menschen in Niedersachsen bestätigt. https://www.nlga.niedersachsen.de/about/pressemitteilungen/erster-fall-von-west-nil-fieber-bei-einem-menschen-in-niedersachsen-bestatigt-235459.html.
27. Rosà R, Marini G, Bolzoni L, Neteler M, Metz M, Delucchi L, Chadwick EA, Balbo L, Mosca A, Giacobini M, Bertolotti L, Rizzoli A. Early warning of West Nile virus mosquito vector: climate and land use models successfully explain phenology and abundance of Culex pipiens mosquitoes in north-western Italy. Parasit Vectors 2014; 7: 269. doi: 10.1186/1756-3305-7-269.
28. Kovach TJ, Kilpatrick AM. Irrigation increases and stabilizes mosquito populations and increases West Nile virus incidence. Sci Rep 2024; 14 (1): 19913. doi: 10.1038/s41598-024-70592-3.
29. Vollans M, Day J, Cant S, Hood J, Kilpatrick AM, Kramer LD, Vaux A, Medlock J, Ward T, Paton RS. Modelling the temperature dependent extrinsic incubation period of West Nile Virus using Bayesian time delay models. J Infect 2024; 89 (6): 106296. doi: 10.1016/j.jinf.2024.106296.
30. Fay RL, Cruz-Loya M, Keyel AC, Price DC, Zink SD, Mordecai EA, Ciota AT. Population-specific thermal responses contribute to regional variability in arbovirus transmission with changing climates. iScience 2024; 27 (6): 109934. doi: 10.1016/j.isci.2024.109934.
31. Paul-Ehrlich-Institut (PEI). Bekanntmachung über die Zulassung von Arzneimitteln - Anordnung von Maßnahmen, die das Risiko der Übertragung einer in Deutschland erworbenen West-Nil-Virus (WNV)-Infektion durch Blutkomponenten zur Transfusion (zelluläre Blutzubereitungen und therapeutische Frischplasmen) und durch Stammzellzubereitungen zur hämatopoetischen Rekonstitution minimieren können. 18.93.2020. https://www.pei.de/SharedDocs/Downloads/DE/newsroom/bundesanzeiger/veroeffentlichungen/2020/banz-at-04-06-2020-b6.html.
32. Faddy HM, Osiowy C, Custer B, Busch M, Stramer SL, Adesina O, van de Laar T, Tsoi WC, Styles C, Kiely P, Margaritis A, Kwon SY, Qiu Y, Deng X, Lewin A, Jørgensen SW, Erikstrup C, Juhl D, Sauleda S, Camacho Rodriguez BA, Coral LJCS, Gaviria García PA, Oota S, O'Brien SF, Wendel S, Castro E, Navarro Pérez L, Harvala H, Davison K, Reynolds C, Jarvis L, Grabarczyk P, Kopacz A, Łętowska M, O'Flaherty N, Young F, Williams P, Burke L, Chua SS, Muylaert A, Page I, Jones A, Niederhauser C, Vermeulen M, Laperche S, Gallian P, Sawadogo S, Satake M, Gharehbaghian A, Addas-Carvalho M, Blanco S, Gallego SV, Seltsam A, Weber-Schehl M, Al-Riyami AZ, Al Maamari K, Alawi FB, Pandey HC, Mbanya D, França RA, Charlewood R; Virology and Surveillance; Risk Assessment and Policy subgroups of the ISBT Working Party on Transfusion‐transmitted Infectious Diseases. International review of blood donation nucleic acid amplification testing. Vox Sang 2024; 119 (4): 315-325. doi: 10.1111/vox.13592.
33. European Centre for Disease Prevention and Control (ECDC). Surveillance, prevention and control of West Nile virus and Usutu virus infections in the EU/EEA. https://www.ecdc.europa.eu/sites/default/files/documents/Surveillance_prevention_and_control_of_WNV_and_Usutu_virus_infections_in_the_EU-EEA.pdf.
Rubrik: Reserveantibiotika im Fokus
Meropenem/Vaborbactam: aktuelle Daten zu Wirksamkeit und Sicherheit des Reserveantibiotikums (S. 59)
1. Fachinformation Vaborem (Meropenem/Vaborbactam). Berlin-Chemie. Stand 07/2023. URL: https://www.medical-hub.berlin-chemie.de/sites/g/files/fugoka451/files/products/documents/147730_vaborem_fi-0723.pdf [09.09.2025]
2. U.S. Food & Drug Administration (FDA). VABOMERE (meropenem and vaborbactam): Full Prescribing Information. Dec 2024. URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/209776s009lbl.pdf [09.09.2025]
3. Kaye, K.S. et al. Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection: The TANGO I Randomized Clinical Trial. JAMA 2018; 319(8):788-799. doi: 10.1001/jama.2018.0438
4. Wunderink, R.G. et al. Effect and Safety of Meropenem-Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial. Infect Dis Ther 2018; 7(4):439-455. doi: 10.1007/s40121-018-0214-1
5. European Medicines Agency (EMA). Assessment report Vabomere (Meropenem/Vaborbactam). Stand 20.09.2018. URL: https://www.ema.europa.eu/en/documents/assessment-report/vabomere-epar-public-assessment-report_en.pdf [09.09.2025]
6. Jin, D. et al. Real-world effectiveness and safety of meropenem-vaborbactam in the treatment of carbapenem-resistant enterobacterales (CRE) infections: a systematic review and meta-analysis. J Chemother 2025; published online Feb 13, 2025. doi: 10.1080/1120009X.2025.2465129
7. Tiseo, G. et al. Real-world experience with meropenem/vaborbactam for the treatment of infections caused by ESBL-producing Enterobacterales and carbapenem-resistant Klebsiella pneumoniae. Eur J Clin Microbiol Infect Dis 2024; published online Feb 20, 2024. doi: 10.1007/s10096-024-04758-2
8. Tumbarello, M. et al. Compassionate use of meropenem/vaborbactam for infections caused by KPC-producing Klebsiella pneumoniae: a multicentre study. JAC Antimicrob Resist 2022; 4(1):dlac022. doi: 10.1093/jacamr/dlac022
9. Tumbarello, M. et al. Outcomes and Predictors of Mortality in Patients With KPC-Kp Infections Treated With Meropenem Vaborbactam: An Observational Multicenter Study. Open Forum Infect Dis 2024; 11(6):ofae273. doi: 10.1093/ofid/ofae273
10. Ackley, R. et al. Meropenem-vaborbactam versus ceftazidime-avibactam for treatment of carbapenem-resistant Enterobacteriaceae infections. Antimicrob Agents Chemother 2020; 64(5):e02313-19. doi: 10.1128/AAC.02313-19.
11. Alosaimy, S. et al. Real-world, Multicenter Experience With Meropenem-Vaborbactam for Gram-Negative Bacterial Infections Including Carbapenem-Resistant Enterobacterales and Pseudomonas aeruginosa. Open Forum Infect Dis 2021; 8(8):ofab371. doi: 10.1093/ofid/ofab371
12. Shields, R.K. et al. Early Experience With Meropenem-Vaborbactam for Treatment of Carbapenem-resistant Enterobacteriaceae Infections. Clin Infect Dis 2020; 71(3):667-671. doi: 10.1093/cid/ciz1131
13. Marino A, Maraolo AE, Mazzitelli M et al. Head-to-head: meropenem/vaborbactam versus ceftazidime/avibactam in ICUs patients with KPC-producing K. pneumoniae infections– results from a retrospective multicentre study. Infection 2025; published online Jul 16, 2025. doi: 10.1007/s15010-025-02608-7
14. Tamma PD, Heil EL, Justo JA, et al. Infectious Diseases Society of America 2024 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections. Clin Infect Dis 2024; published online Aug 7, 2024. doi: 10.1093/cid/ciae403
15. Paul, M. et al. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine). Clin Microbiol Infect 2022; 28(4): 521-547. doi: 10.1016/j.cmi.2021.11.025
